Nabi Biopharmaceuticals (NASDAQ:NABI)

CAPS Rating: 4 out of 5

The Company leverage its experience and knowledge in powering the human immune system to develop and market products that target serious medical conditions in the areas of transplantation, infectious disease and hematology/oncology.

Recs

0
Player Avatar ipsiety (< 20) Submitted: 7/22/2011 11:11:14 AM : Outperform Start Price: $2.03 NABI Score: -20.55

100m cash and 85m cap.

Featured Broker Partners


Advertisement